×
Dr. Kopetz on Updated Data From BEACON CRC Study in BRAF V600E
https://www.onclive.com/conference-coverage/asco-2020/dr-kopetz-on-updated-data-from-beacon-crc-study-in-braf-v600emutant-crc
Onclive.com

May 28th, 2020 - The updated survival data that was presented at the 2020 ASCO Virtual Scientific Program includes 6 months of additional follow-up and response data for all patients randomized in the trial, says Kopetz. Previously, investigators had reported only the first half of the patients as per the pre-planned analysis. This report includes updated survival data with more mature follow-up.

Colorectal cancer: Improving screening in rural clinic.
https://meetinglibrary.asco.org/record/190695
Thuy Thanh Thi Le, DO

May 28th, 2020 - Background: Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States. From 2010 to 2014, CRC was also the second leading cause of cancer deaths in North Carolina (NC). Between 2012-2016, the age adjusted mortality rate was 18-25 per 100,000 persons in Robeson County, NC. During this timeframe, it is estimated that if all people aged 50 and older in NC we...

Utility of neutrophil to lymphocyte ratio in predicting colorectal cancer prognosis at a VA hospital: Do stage and sidedness matter?
https://meetinglibrary.asco.org/record/188128
Kee-Hwan Michael Kim

May 28th, 2020 - Background: Pretreatment neutrophil-lymphocyte ratio (pNLR) has been shown to associate with prognosis in patients with colorectal cancer (CRC). We asked if pNLR equally predicted prognosis in CRC regardless of stage and tumor location. We also asked if pNLR changed with time, especially within one year of diagnosis. Methods: Retrospective clinical data including age at diagnosis, pathological ...

Predictive and prognostic factors of apatinib in metastatic colorectal cancer.
https://meetinglibrary.asco.org/record/189184
Fen Wang, MD

May 28th, 2020 - Background: It has been extremely challenging to identify suitable predictive or prognostic factors of anti-VEGF agents. Apatinib, a vascular endothelial growth factor receptor 2(VEGFR-2) inhibitor, showed promising efficacy in chemo-refractory metastatic colorectal cancer (mCRC) patients in a phase II trial. The aim of current study was to identify the potential predictive and prognostic facto...

Prognostic significance of adipose tissue distribution and metabolic activity in PET-CT images of patients with metastatic colorectal cancer.
https://meetinglibrary.asco.org/record/188557
Tuba Karacelik, Asistant

May 28th, 2020 - Background: The metabolic activity in visceral and subcutaneous adipose tissue have different metabolic risk profiles for colorectal cancer. The aim of this study was to investigate the prognostic significance of adipose tıssue distribution and metabolic activity in PET-CT and predict the overall survival in patients with metastatic colorectal cancer (mCRC). Methods: A total of 83 patients diag...

Role of palliative radiotherapy in patients with metastatic colorectal cancer: A propensity score matching analysis.
https://meetinglibrary.asco.org/record/188467
Zhenyu Lin, MD

May 28th, 2020 - Background: To explore whether palliative radiotherapy can further improve overall survival (OS) of patients with metastatic colorectal cancer (mCRC) receiving systemic treatment and analyze its survival prognostic factors. Methods: The demographics, tumor characteristics, and survival outcomes of 484 mCRC patients who underwent systemic treatment with or without palliative radiotherapy from De...

The role of combined treatment of metastatic colorectal cancer inpatients with liver metastases.
https://meetinglibrary.asco.org/record/189190
Mikhail Trandofilov

May 28th, 2020 - Background: Combined treatment for patients with metastatic colorectal cancer (mCRC) offers better long-term outcomes and chemotherapy can increase the rate of hepatic resectability for patients with initially inoperable disease. Methods: The analysis included 132 patients diagnosed with mCRC having metastases in the liver treated from 2015 to 2020. Of these, 62 (47%) were men and 70 (53%) wome...

A new CRISPR mediated intestinal tumor mouse model targeting four canonical tumor suppressor genes.
https://meetinglibrary.asco.org/record/189076
Hajime Kashima, M.D., Ph.D.

May 28th, 2020 - Background: Mouse models of intestinal tumorigenesis have been developed and many of them involve mutations in the Apc gene. However, human intestinal tumors contain multiple additional sporadic mutations in tumor suppressor genes (TSGs). Our goal is to develop a novel mouse model of intestinal tumorigenesis that can recapitulate the natural history of mutations in diverse stages of tumor devel...

Deviation from the precisely timed phenomic ageotypes can assist in early CRC screening and reveal underlying pathophysiology.
https://meetinglibrary.asco.org/record/188713
Sheeno P. Thyparambil, PhD

May 28th, 2020 - Background: Human serum proteome and metabolome profiles have been analyzed to explore the molecular changes that occur with aging. We hypothesized that deep phenomic profiling of longitudinal sera would allow the identification of distinct phenomic chronologic patterns as a normal biological clock baseline to study personal aging. We further hypothesized that molecular assessment of this chron...

Phase II trial of induction chemotherapy plus chemoradiotherapy with aspirin or placebo in high-risk rectal cancer (ICAR).
https://meetinglibrary.asco.org/record/189091
Juliana Souza, MD, MD

May 28th, 2020 - Background: Induction chemotherapy (IC) followed by chemoradiation (CRT) is an attractive approach in locally-advanced, high-risk rectal cancer. Additionally, aspirin has shown potential to lower recurrence rate in colorectal cancer, and improve outcomes alongside CRT in rectal cancer, with higher rate of tumor downstaging. Methods: Randomized, double-blind phase 2 trial to evaluate induction t...

A multicenter, open-label, phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of JMT-101 in patients (pts) with advanced colorectal cancer (ACC).
https://meetinglibrary.asco.org/record/188532
Jian Li, MD

May 28th, 2020 - Background: JMT101 is a fully human monoclonal IgG1 antibody targeting epidermal growth factor receptor (EGFR). This study aimed to evaluate the safety and tolerability of JMT101 alone or in combination with chemotherapy in ACC. Methods: This is an open label, dose-escalating, phase I clinical trial. The pts with ACC and naïve to systemic EGFR-targeted therapy were assigned to receive JMT101 mo...

20q amplification defined by genomic and clinical characteristics as a subgroup with increased prevalence and better survival in metastatic colorectal cancer.
https://meetinglibrary.asco.org/record/188614
Satish Maharaj, MBBS

May 28th, 2020 - Background: Genomic instability from 20q amplification is an oncogenic pathway in colorectal cancer (CRC). Several genes have been implicated, including BCL2L1, AURKA, SRC, ASXL1, GNAS and TOP1. There is a lack of data regarding 20q amplified group and one study implicating these genes suggested these patients have better overall survival. Next Generation Sequencing (NGS) has become widely used...

Clinically relevant multi-omic analysis of colorectal cancer.
https://meetinglibrary.asco.org/record/188610
Silvia von der Heyde

May 28th, 2020 - Background: Cancer is a highly heterogeneous disease, both intra- and inter-individually consisting of complex phenotypes and systems biology. Although genomic data has contributed greatly towards the identification of cancer-specific mutations and the progress of precision medicine, genomic alterations are only one of several important biological drivers of cancer. Furthermore, single-layer om...

The prognosis valve of tumor regression grade in the same ypStage patients after neoadjuvant treatment in locally advanced rectal cancer: Post-hoc analysis of a prospective trial.
https://meetinglibrary.asco.org/record/188604
Jianwei Zhang, MD

May 28th, 2020 - Background: The ypStage after neoadjuvant treatment was an important prognosis factor in locally advanced rectal cancer (LARC). pCR or ypStage 0 showed best prognosis, while ypStage II-III showed poor prognosis and further adjuvant chemotherapy with FOLFOX was recommended. Tumor regression grade (TRG) was another factor to evaluate the response to neoadjuvant treatment. Even in the same ypStage...

Racial and socioeconomic disparities in overall survival in colorectal cancer (CRC) at West Cancer Center & Research Institute (WCCRI), Memphis, TN.
https://meetinglibrary.asco.org/record/188437
Vanessa Wookey, MD

May 28th, 2020 - Background: WCCRI, a comprehensive regional community oncology center in Memphis, Tennessee and the Mid-South region, serves a racially, geographically and socioeconomically diverse patient cohort. We sought to evaluate disparity of outcomes in survival by race and socioeconomic status, in addition to patient and tumor characteristics. Methods: All consecutive patients referred to and treated a...

Clinical utility of germline genetic testing after tumor genomic testing in colorectal cancer patients.
https://meetinglibrary.asco.org/record/189123
Nhu Ngo, MD

May 28th, 2020 - Background: Practice guidelines support genomic and biomarker testing of colorectal cancer (CRC) to inform treatment options in advanced disease and to screen for MMR deficiency/MSI/Lynch syndrome. As yet, guidelines for follow-up germline testing are not well established. In 2019 ESMO recommended reflex germline testing when pathogenic variants (PV) were found in any of 27 cancer susceptibilit...

Exosomal marker CD63 expression pattern using immunohistochemistry (IHC) in patients with rectal adenocarcinoma in comparison with left-sided colon cancer.
https://meetinglibrary.asco.org/record/188526
Pranitha Prodduturvar, MBBS, MD

May 28th, 2020 - Background: Adenocarcinomas arising from the distal one third of the transverse colon, splenic flexure, descending colon, sigmoid colon and rectum are often grouped together due to their hindgut embryologic origin and referred to as left-sided colorectal cancer (CRC). Rectal cancer represents a subset of CRC that has distinct differences in anatomical location, clinical behavior, prognosis and ...

Survival among colorectal cancer patients with a history of previous cancer.
https://meetinglibrary.asco.org/record/188476
Sandi Pruitt, PhD

May 28th, 2020 - Background: A growing number of patients with colorectal cancer (CRC) have survived a previous cancer. Although little is known about their prognosis, this population is frequently excluded from clinical trials. We examined the impact of previous cancer on overall and cancer-specific survival in a population-based cohort of patients diagnosed with incident CRC. Methods: We identified patients a...

Mismatch repair deficiency testing in colorectal cancer and factors associated with nonadherence to guidelines.
https://meetinglibrary.asco.org/record/188012
Phuong Ngo, MD

May 28th, 2020 - Background: Mismatch repair (MMR) deficiency is characteristic of Lynch syndrome, which typically affects patients < 50 years old with colorectal cancer (CRC) but can also occur in sporadic CRC. MMR deficiency causes microsatellite instability (MSI) and affects therapy response and prognosis. Guidelines now recommend universal testing of MMR/MSI in all CRC patients, but universal testing has no...

Patient-initiated approach to prevent oxaliplatin induced peripheral neuropathy: A social media experiment.
https://meetinglibrary.asco.org/record/188651
Dana Cardinas, DPM, FACFAS

May 28th, 2020 - Background: Oxaliplatin continues to be the standard of care in the adjuvant and palliative setting in colorectal cancer (CRC). Although effective in CRC treatment, it is associated with a high risk of chemotherapy induced peripheral neuropathy (CIPN), which can debilitate the patient, prevent completion of care, and deteriorate their quality of life. Methods: Colontown is a Facebook-based CRC ...